Syngene has considerable experience in peptide development including state-of-the-art analytical instruments for peptide purification and characterization. Our experience in Peptide development is as follows:
- Linear peptides: Up to 50 residues, up to g scale, purity > 95%
- Disulfide rich peptides (linear and cyclotides)
- Library of 50 compounds (20-50 mg, >95%)
- Branched chain peptides
- Cyclic peptides: Amides, lactams, disulfide bridge, stapled peptides
- N-Terminal and C-Terminal modification
- Phosphorylated peptides
- PEG, fluorescein, biotin labeled peptides
- Peptides linked to bifunctional chelating agents such as DOTA, DTPA and AAZTA
- Ligation: NCL and KAHA ligation
Accelerating Peptide supply by Integrating Drug Substance (DS) and Drug Product (DP)
Syngene has used its wealth of experience and knowledge in Peptide API development and manufacture (DS), as well as Clinical / Commercial drug product (DP) development and manufacturing, to create a fully integrated program for clinical / commercial supply. The figure below shows how we can perform development workflows in parallel in the same facility, and under the same quality system. The enhanced knowledge sharing and consolidation of activities speeds up the development cycle to provide clinic or commercial ready Peptide Drug Product. Primarily aimed at the exciting Radio-Theranostic peptide space, we can also cater for much larger integrated peptide and peptide conjugate projects as well.
